12:00 AM
 | 
Aug 05, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Tanezumab: Phase III start

Pfizer disclosed on a conference call to discuss its 2Q13 earnings that it plans to resume Phase III trials next year of tanezumab for chronic pain. The pharma said FDA lifted a partial clinical hold last month on the compound. FDA placed a partial...

Read the full 200 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >